Introducing SubMagna™ SL HMW, PCCA's Newest Base
PCCA Products
•
58m
The wait is over! Join PCCA Director of Research & Development Daniel Banov, RPh, to learn the science behind our newest base – SubMagna™ SL HMW.
Developed to provide an alternative dosing delivery system for commercially available semaglutide, tirzepatide and a broad range of other APIs, this base offers even more opportunities for compounders!
The anhydrous, self-emulsifying sublingual suspension vehicle provides the opportunity to circumvent gastrointestinal factors that can influence the bioavailability of APIs. Its permeation-enhancing and unique mucoadhesive properties help drive molecules into mucosal tissue, potentially driving greater drug absorption and offering increased API-to-tissue contact time.
Up Next in PCCA Products
-
Navigating the Lab with Methylene Blu...
Learn best practices that can enhance your experience compounding with methylene blue. Senior Formulations Specialist Stacey Lemus, BS, will present techniques developed by our Formulations teams in lab that can ease the sometimes stressful process of working with this vibrant API. This webinar i...
-
Drive Pharmacy Growth
Are you looking to drive growth in your compounding pharmacy?
Join us for this FREE webinar, led by PCCA Director of Business Solutions Laura Pfaffenberger, PharmD, that will equip you with actionable strategies and essential tools to boost patient outcomes, enhance prescriber relationships, eng...
-
2024 Kickoff: Game-Changing Opportuni...
How can you make sure your pharmacy crushes it throughout 2024?
Let the key insights and opportunities featured in our FREE webinar, 2024 Kickoff: Game-Changing Opportunities for Your Pharmacy, be your formula for success all year long.
Join us for valuable strategies and the scoop on:
5 tips ...
